THOR-707 + Pembrolizumab

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Classic Hodgkin Lymphoma

Conditions

Classic Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma

Trial Timeline

Dec 7, 2021 → Sep 6, 2024

NCT ID

NCT05179603

About THOR-707 + Pembrolizumab

THOR-707 + Pembrolizumab is a phase 2 stage product being developed by Merck for Classic Hodgkin Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05179603. Target conditions include Classic Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma.

What happened to similar drugs?

0 of 3 similar drugs in Classic Hodgkin Lymphoma were approved

Approved (0) Terminated (1) Active (2)

🔄Camrelizumab + Investigator's choice of ChemotherapyJiangsu Hengrui MedicinePhase 3

🔄Sintilimab + Carboplatin + Etoposide + Ifosfamide + Placebo + Carboplatin + Etoposide + IfosfamideInnovent BiologicsPhase 3

❌Tislelizumab + Salvage ChemotherapyBeOne MedicinesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05179603	Phase 2	Terminated	Dec 7, 2021	Sep 6, 2024	Classic Hodgkin Lymphoma
NCT04914897	Phase 2	Terminated	Sep 23, 2021	Oct 17, 2024	Pleural Mesothelioma

Competing Products

15 competing products in Classic Hodgkin Lymphoma

See all competitors

Product	Company	Stage	Hype Score
Camrelizumab + Investigator's choice of Chemotherapy	Jiangsu Hengrui Medicine	Phase 3	36
Sabestomig (AZD7789)	AstraZeneca	Phase 1	29
Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Brentuximab vedotin	Merck	Phase 2	42
Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin + Etoposide + Cyclophosphamide + Vincristine + Procarbazine + Prednisone	Merck	Phase 2	35
Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine Sulfate	Merck	Phase 2	31
Carboplatin + Etoposide + Ifosfamide + Pembrolizumab	Merck	Phase 2	31
Pembrolizumab (+) Berahyaluronidase alfa	Merck	Phase 2	39
Panobinostat	Novartis	Phase 2	35
PD1	Innovent Biologics	Phase 2	35
Sintilimab + Carboplatin + Etoposide + Ifosfamide + Placebo + Carboplatin + Etoposide + Ifosfamide	Innovent Biologics	Phase 3	36
Nivolumab + Autologous CD30.CAR-T + Fludarabine + Bendamustine	Bristol Myers Squibb	Phase 1	33
Nivolumab + Ipilimumab	Bristol Myers Squibb	Phase 2	31
AK129 + AK117	Akeso	Phase 1/2	39
Tislelizumab + Salvage Chemotherapy	BeOne Medicines	Phase 3	29
GEN3017	Genmab	Phase 1/2	21